Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes. Randomized, open label pilot study.
Phase of Trial: Phase IV
Latest Information Update: 15 Jun 2018
At a glance
- Drugs Tofogliflozin (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 12 Jun 2018 Status changed from not yet recruiting to recruiting.
- 26 Dec 2017 New trial record